



## **For Immediate Release**

### **Symic Bio to Present at the 28<sup>th</sup> Annual Piper Jaffray Healthcare Conference**

**SAN FRANCISCO, Nov. 22, 2016** – Symic Bio, a clinical stage biopharmaceutical company focused on extracellular matrix biology developing a new category of therapeutics, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline and progress at the upcoming Piper Jaffray Healthcare Conference.

Conference details are as follows:

Date: Tuesday, November 29, 2016

Time: 7:30 a.m. EST

Location: Lotte New York Palace, New York

#### **About Symic Bio**

Symic Bio is a clinical stage biopharmaceutical company focused on extracellular matrix biology that is developing a new category of therapeutics. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules of the extracellular matrix. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061 directed at disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.

For additional information please visit the company's website at [www.symic.bio](http://www.symic.bio), LinkedIn page at [www.linkedin.com/company/symic-bio](http://www.linkedin.com/company/symic-bio) or follow on Twitter at [www.twitter.com/symicbio](http://www.twitter.com/symicbio).

###

#### **Investor Contacts**

Lisa Burns or Bill Slattery, Jr.

Burns McClellan, Inc.

(212) 213-0006

[ir@symic.bio](mailto:ir@symic.bio)

**Media Contacts**

David Schull or Rich Allan

Russo Partners, LLC

(212) 845-4271

(646) 942-5588

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

[rich.allan@russopartnersllc.com](mailto:rich.allan@russopartnersllc.com)

###